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A B S T R A C T   
"Life is an instantaneous encounter of circulating matter and flowing energy" (Jean Giaja, Serbian physiologist), 
is one of the most elegant definitions not only of life but the relationship of redox biology and metabolism. Their 
evolutionary liaison has created inseparable yet dynamic homeostasis in health, which, when disrupted, leads to 
disease. This interconnection is even more pertinent today, in an era of increasing metabolic diseases of epidemic 
proportions such as obesity, metabolic syndrome, and diabetes. Despite great advances in understanding the 
molecular mechanisms of redox and metabolic regulation, we face significant challenges in preventing, diag-
nosing, and treating metabolic diseases. The etiological association and temporal overlap of these syndromes 
present significant challenges for the discrimination of appropriate clinical biomarkers for diagnosis, treatment, 
and outcome prediction. These multifactorial, multiorgan metabolic syndromes with complex etiopathogenic 
mechanisms are accompanied by disturbed redox equilibrium in target tissues and circulation. Free radicals and 
reactive species are considered both a causal factor and a consequence of disease status. Thus, determining the 
subtypes and levels of free radicals and reactive species, oxidatively damaged biomolecules (lipids, proteins, and 
nucleic acids) and antioxidant defense components as well as redox-sensitive transcription factors and fluxes of 
redox-dependent metabolic pathways will help define existing and establish novel redox biomarkers for strati-
fying metabolic diseases. This review aims to discuss diverse redox/metabolic aspects in obesity, metabolic 
syndrome, and diabetes, with the imperative to help establish a platform for emerging and future redox- 
metabolic biomarkers research in precision medicine. Future research warrants detailed investigations into the 
status of redox biomarkers in healthy subjects and patients, including the use of emerging ’omic’ profiling 
technologies (e.g., redox proteomes, lipidomes, metabolomes, and transcriptomes), taking into account the in-
fluence of lifestyle (diet, physical activity, sleep, work patterns) as well as circadian ~24h fluctuations in cir-
culatory factors and metabolites.   
1. Introduction 
Modern human medicine faces numerous challenges, despite the 
explosive progress of diagnostic and therapeutic approaches. Our ability 
to gain an in-depth understanding of the molecular basis of various 
pathological conditions has opened diverse research avenues and many 
questions that require urgent answers. If we were to allow ourselves 
some scientific skepticism, we would ascertain the fact that even after 
almost a hundred years since the discovery of insulin and despite much 
scientific progress, we still live in a pandemic of diabetes, especially type 
2. The forecasts for the coming decades are not promising either. In 
parallel with type 2 diabetes mellitus (T2DM), another two conditions 
strongly associated with it – obesity and metabolic syndrome, paint the 
same picture of a pandemic with predictions of exponential growth in 
the future. 
Each of these three conditions is complex in itself. The challenges we 
face are further compounded because these conditions can occur 
concomitantly while their underlying mechanisms often overlap. The 
complexity is multifactorial, whether we consider the etiology, clinical 
manifestations, or complex therapeutic approaches. For these reasons, 
we do not regard diabetes and obesity as classic diseases but rather as 
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syndromes, including metabolic syndrome. When we take a compre-
hensive look at this triad, the scope of the problem reaches the level of 
multi-metabolic disorder/syndrome. Systemic metabolic dysregulation 
is initiated by the disturbances in several physiological systems, pri-
marily those with endocrine functions. This includes various organs, 
predominantly white adipose tissue (WAT, specific morpho-functional 
depots), brown adipose tissue, pancreas, liver, and muscles. 
The modern concept of redox biology and medicine also faces a 
number of challenges. The traditional concept where reactive species are 
viewed primarily in the light of oxidative damage they inflict on bio-
molecules is "distant" history. Indeed, reactive species are essential 
signaling molecules involved in almost every physiological process, 
from cell division and differentiation to metabolic regulation. Through 
direct and indirect action, they modulate the activity and function of 
biomolecules (proteins, lipids, nucleic acids) and redox-sensitive tran-
scription factors, inducing an endogenous adaptive response in cells, 
including the antioxidant defense. The redox homeostasis of cells and 
their extracellular environments is determined by the degree of reactive 
species production and neutralization that are firmly coupled with 
(oxidative) metabolism. At the regulatory level, the relationship be-
tween reactive species production and metabolism is bidirectional and 
dynamic. Setting the redox state of cells is vital in health as much as in 
disease and opens redox-based therapeutic avenues for treating meta-
bolic diseases such as obesity, metabolic syndrome, and diabetes. 
2. "Clinical" versus redox biomarkers 
Ever since Claude Bernard postulated the "constancy of the internal 
environment" [1], we have been searching for (bio)markers of homeo-
stasis whose change indicates disease. Many of them in obesity, meta-
bolic syndrome, and diabetes (i.e., levels of insulin, glucose, free fatty 
acids, triacylglycerol, cholesterol, glycosylated hemoglobin-HbA1c) are 
clinical biomarkers that are routinely used in diagnostics in human 
medicine. Their changes are a reflection of complex metabolic distur-
bances, predominantly in the most affected tissues. Because their cir-
culatory levels are dynamic in healthy individuals, it is not always 
straightforward to relate their circulatory changes in patients to path-
ological conditions. 
The search for redox biomarkers that are clinically relevant is an 
imperative task of redox biology in regards to human medicine. How-
ever, when we discuss the utility of redox biomarkers, some consider-
ations deserve attention. First of all, what is considered under the term 
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redox biomarkers? Precisely what and where do we measure? What can 
we feasibly measure in humans? Redox biomarkers can include a diverse 
range of measurements from reactive species (that are often difficult to 
determine due to their nature and short life) and antioxidant defense 
components (enzymatic and non-enzymatic) to stable end-products of 
the oxidative modifications of proteins, lipids, and nucleic acids as well 
as concentrations of iron (free and bound) and those of other transition 
metals. They are primarily determined in the circulation (plasma/ 
serum, erythrocytes, monocytes, platelets), urine, or saliva. Changes in 
their status are a reflection of corresponding changes in their concen-
tration, expression, activity, or localization in affected tissues. 
Outstanding reviews of methodological aspects and theoretical consid-
erations for potential redox-dependent biomarkers are provided by 
Halliwell [2], Poulsen et al. [3], and Wang et al. [4]. 
When it comes to metabolic diseases, we face many difficulties in 
defining and validating redox biomarkers. To precisely define existing 
and discover novel redox biomarkers, it is necessary to achieve a better 
understanding of the molecular mechanisms of redox-dependent meta-
bolic processes in target tissues and organs as well as those involved in 
inter-organ communication. 
3. Clinical criteria to define a complex landscape of obesity, 
metabolic syndrome, and diabetes 
Body mass index (BMI) is a useful population-level measure of 
overweight state and obesity in medical practice. However, metabolic 
alterations at the core of insulin resistance (IR) and T2DM pathophysi-
ology may develop over the broad continuum of BMI. Nevertheless, it is 
now well accepted that obesity becomes a metabolic disease once the 
adaptive lipid-storing function of adipose tissue fails [5]. To emphasize 
the importance of lipid-storage malfunction, as much as the overall 
excess of adipose tissue in metabolic disorders, overweight state and 
obesity are now defined as "excessive or abnormal fat accumulation that 
presents a health risk" by the World Health Organisation [6]. Hetero-
geneity of the obese state was attributed to the differences in adipose 
tissue accumulation back in 1947 when it was first noticed that 
apple-shaped (mostly men) subjects are more likely to develop diabetes 
and other health complications than their pear-shaped (mostly women) 
counterparts [7]. Today still, the anthropometric measurements of BMI, 
waist circumference (WC), and waist-to-hip ratio (WHR) are used by 
most healthcare institutions to define abdominal obesity with high 
metabolic risk [8]. Apart from the genetic background, the upsurge in 
abdominal obesity during the last several decades is a direct result of an 
excess in available energy that impairs the metabolic function of adipose 
tissue. Exceeded functional capacity of highly insulin-sensitive adipose 
tissue (subcutaneous) to store lipids causes visceral and ectopic lipid 
deposition in muscle, liver, and other organs, further aggravating insulin 
resistance and perpetuating prediabetic conditions (Fig. 1). 
According to the American Diabetes Association, a prediabetic state 
is clinically defined by impaired fasting glucose (IFG) level and impaired 
glucose tolerance (IGT) test. IFG level of 100–125 mg/dL and IGT of 
140–199 mg/dL plasma glucose, respectively, indicate prediabetes. 
However, the prediabetic state is characterized by a combination of 
different and overlapping clinical conditions that often congregate, 
thereby increasing the risk of diabetes onset. The gathering of interre-
lated metabolic risk factors such as atherogenic dyslipidemia (elevated 
serum triacylglycerol and apolipoprotein B), increased small low- 
density lipoprotein (LDL) particles, reduced level of high-density lipo-
protein (HDL) and cholesterol, and elevated blood pressure and plasma 
glucose, is known as metabolic syndrome. This pleiad of metabolic risk 
factors often develops due to another set of underlying risk factors – 
obesity and insulin resistance. Although the risk of T2DM generally in-
creases with increasing insulin resistance and obesity, it has been widely 
accepted that T2DM development depends on adipose tissue function 
Fig. 1. Adipose tissue - centric pathogenesis of 
type 2 diabetes. In health, postprandially, excess fat 
is stored in adipose tissue, limiting its deposition in 
other tissues. In obesity (1), due to energy excess, the 
number of hypertrophic adipocytes increases when 
counteractive metabolic and hyperplastic responses 
are surpassed, and the expanding and lipid-buffering 
capacity of adipose tissue fails (2). Unrestrained 
postprandial lipolysis and low oxidative capacity 
drive systemic free fatty acid (FFA) (3) and pro- 
inflammatory adipocytokine delivery to non-adipose 
tissues (4). Consequently, muscles, liver, and 
pancreas are faced with ectopic lipid deposition and 
lipotoxicity (5), which ultimately interferes with 
multiple regulatory mechanisms of glucose storage in 
muscles and liver. In parallel, the pancreas releases 
more insulin to sustain normoglycaemia (6). If such 
conditions persist, compensatory pancreatic hyperse-
cretion of insulin fails, and signs of hyperglycemia 
occur. Initially only transiently, in postprandial state 
(defined as impaired glucose tolerance), and later 
persistently, regardless of the nutritional state, 
resulting in overt type 2 diabetes mellitus (T2DM) 
(7). Subjects with an excess of upper-body or visceral 
adiposity (right) are more prone to develop metabolic 
syndrome and type 2 diabetes for a given body mass 
index (BMI), as these "metabolically obese" in-
dividuals suffer from a low expanding capacity of 
lower-body or subcutaneous adiposity. In clinical 
practice, this state is crudely defined by a higher 
waist-to-hip ratio (WHR).   
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rather than obesity per se. Accordingly, some people that appear normal- 
weight are insulin resistant and are thereby described as "metabolically 
obese" [9]. Similarly, obese people that are insulin sensitive are 
described as "metabolically healthy obese" [10]. These transient meta-
bolic phenotypes - with or without IR, and with or without obesity 
(defined by BMI) complicate metabolic syndrome diagnostics and T2DM 
risk predictions (Fig. 2). 
Diabetes mellitus is a chronic metabolic disease characterized by 
hyperglycemia, defined either by HbA1c ≥ 6.5%, or fasting plasma 
glucose (FPG) FPG ≥126 mg/dL or the 2h plasma glucose after a 75 g 
oral glucose tolerance test (OGTT) ≥200 mg/dL. If left untreated, hy-
perglycemia leads to severe health complications increasing all-cause 
mortality. Diabetes can be broadly classified into two main categories: 
type 1 diabetes mellitus (T1DM), which occurs due to autoimmune or 
idiopathic β-cell destruction, usually leading to absolute insulin defi-
ciency (accounts for ~24% cases), and T2DM, which develops due to a 
progressive insulin secretory defect in the background of insulin resis-
tance, from a "stealthy" prediabetic state (accounts for ~76% cases) 
[11]. 
Obesity-associated T2DM, as well as the other obesity-associated 
diseases, can be prevented. The earlier the disease is recognized, the 
greater the successes of prevention and treatment. However, early 
symptoms are often missed. The global prevalence of diabetes is rising, 
currently affecting ~451 million adults worldwide, while according to 
the Center for Disease Control and Prevention, more than 84% of pre-
diabetic patients are not even aware of their condition [12]. Since T2DM 
is strongly related to obesity, the risk of diabetes is easily overlooked in 
subjects who appear to be non-obese (according to BMI). Approximately 
23% of the non-obese population is, however, metabolically obese [13]. 
These non-obese subjects are metabolically obese since they have 
visceral obesity, lower energy expenditure, dyslipidemia, insulin resis-
tance, and higher diabetic risk than some obese counterparts, but may 
escape detection because they have normal BMI [14]. Therefore, new 
diagnostic approaches should be implemented in diabetes diagnostics, 
especially in complex prediabetic conditions. 
4. Redox basis of glucotoxicity and lipotoxicity 
Physical inactivity, aging, and obesity present major risk factors for 
T2DM development. Continuous high-calorie food intake creates 
chronic hyperglycemia and hyperlipidemia that gradually deteriorates 
insulin sensitivity and secretion, leading to overt T2DM. During T2DM 
pathogenesis, especially in advanced stages of T2DM, hyperglycemia- 
related oxidative stress is one of the leading causes of metabolic and 
endocrine disturbances as well as cellular damage in affected tissues. 
Glucose overload increases all pathways of glucose breakdown, leading 
to the accumulation of NADH and FADH2. This puts pressure on the 
electron transport chain (ETC) complexes and increases their reduction 
state. Subsequently, the electrochemical potential across the inner 
mitochondrial membrane causes electron leakage at complexes I, II, and 
III, leading to superoxide anion radical (O2•− ), hydrogen peroxide 
(H2O2), and hydroxyl radical (HO•) production (Fig. 3). The elevated 
levels of reduced NADH as well as reactive oxygen and nitrogen species 
(ROS and RNS, respectively) inactivate glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), resulting in blockage of the glycolytic 
pathway and glyceraldehyde 3-phosphate accumulation. Glyceralde-
hyde 3-phosphate is a glycolytic intermediate and the main precursor for 
methylglyoxal synthesis. The accumulation of antecedent glycolytic 
metabolites, in turn, activates alternative pathways of glucose meta-
bolism (polyol-, hexosamine- and advanced glycation pathways), addi-
tionally increasing reactive oxygen and nitrogen species (RO(N)S) 
production. The polyol pathway causes NADPH depletion associated 
with low glutathione reductase (GR) activity [15], while diminished 
levels of reduced glutathione (GSH) compromise cellular antioxidant 
capacity resulting in elevated levels of RO(N)S and oxidative damage. 
Therefore, reductive stress followed by oxidative stress is a leading hy-
pothesis on the mechanism of hyperglycemia-induced metabolic syn-
drome [16]. Oxidative, carbonyl, and glycation stress induced by 
advanced glycation end products (AGE) and reactive dicarbonyls foster 
pathogenesis and complications of T2DM. AGEs bind to specific cell 
surface receptors of AGE (RAGE), causing alterations in respective 
signaling pathways and promoting intracellular RO(N)S production. 
Methylglyoxal is a strong glycating agent that reacts with arginine res-
idues in proteins. Higher plasma concentrations of methylglyoxal un-
derlie carbonyl stress-induced cardiovascular complications in patients 
with advanced diabetes [17] and "metabolically healthy obese" subjects 
[18]. High levels of methylglyoxal result from increased production and 
lower levels/activity of glyoxalases, GSH-dependent enzymes that 
metabolize methylglyoxal, and other reactive oxoaldehyde metabolites. 
This is usually accompanied by a decrease in aldehyde reductase, the 
enzyme responsible for the detoxification of carbonyl compounds [19]. 
In general, glucotoxicity implies activation of alternative glucose 
oxidation pathways that induce oxidative, carbonyl, and nitrosative 
stresses by enhancing free radical production or impairing antioxidant 
defense. Detailed mechanisms of impaired redox homeostasis in T2DM 
due to hyperglycemia are reviewed in recent papers [16,19–21]. 
Fig. 2. Types of obesity in respect to metabolic 
phenotype and respective risk of type 2 diabetes. 
According to body composition (defined by BMI and 
WHR) and metabolic profile (defined by HOMA-IR 
index and lipid profile), at least 4 types of metabolic 
states/phenotypes can be defined (I-IV). People who 
appear normal-weight can be insulin resistant and 
therefore designated as "metabolically obese" normal- 
weight (III). In addition, obese people who are insulin 
sensitive are designated as "metabolically healthy" 
obese (II). Transient metabolic phenotypes - with or 
without insulin resistance and with or without obesity 
should be considered in predictions of T2DM devel-
opment. T2DM: type 2 diabetes mellitus; BMI: body 
mass index; HOMA-IR: Homeostatic Model Assess-
ment of Insulin Resistance; WHR: waist-to-hip ratio.   
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As a consequence of adipose tissue lipid storage dysfunction in 
obesity-associated metabolic syndrome, increased circulatory FFA 
reposit in visceral fat, liver, muscle, and pancreatic β-cells, forming 
ectopic lipid deposits and causing lipotoxicity [22]. More than 50 years 
ago, it was postulated that plasma FFA delivery and fatty acid oxidation 
in muscles increase the mitochondrial acetyl CoA/CoA and 
NADH/NAD+ ratio, which in turn inactivates rate-controlling enzymes 
in glycolysis, ultimately resulting in the accumulation of glucose 6-phos-
phate [23]. It has been hypothesized that glucose 6-phosphate inhibits 
hexokinase II activity, increasing intracellular glucose concentrations 
and finally leading to decreased glucose uptake and glycogen synthesis. 
The subsequent studies gave complementary evidence that impaired 
glucose transport activity precedes fatty acid oxidation and represents 
the primary defect in insulin insensitivity and impaired glycogen syn-
thesis in muscles [24–27]. It appears that fatty acids taken from the 
circulation are first esterified and deposited as triacylglycerols and, after 
that, retrieved and oxidized [28]. When this ectopic pool of intracellular 
fat in muscles and other organs like the liver or pancreas exceeds critical 
levels, it causes lipotoxicity. In lipotoxicity, fatty acids and other lipid 
metabolites, such as diacylglycerol (DAG), ceramide, long-chain acyl--
coenzyme A, lipid aldehydes, increase oxidative stress via numerous 
intracellular mechanisms. DAGs act as direct activators of protein kinase 
C (PKC) and other stress-sensitive serine/threonine kinases that impair 
tyrosine phosphorylation of insulin receptor substrate (IRS) and insulin 
signaling [29–31]. PKC and other stress-activated protein kinases 
(SAPK) increase the overproduction of nitric oxide (NO) via inducible 
nitric oxide synthase (iNOS), resulting in nitrosative/nitrative stress 
[32]. Notably, one of the main features of lipotoxicity implies the 
accumulation of reactive lipid aldehydes, including the 4-hydroxynone-
nal (4-HNE) and malondialdehyde (MDA) and subsequent protein 
carbonylation [33]. In addition to the described mechanisms, there are 
numerous cellular sources of oxidative stress, including the endoplasmic 
reticulum stress, several stress-activated kinases, AGEs, iNOS, NADPH 
oxidases, xanthine oxidase, mitochondrial ETC, peroxisomes, lipid per-
oxidation, carbonylation related to lipotoxicity, and calcium signaling. 
Intensive research indicates a strong bidirectional link between calcium 
levels and RO(N)S production, pointing out that this interplay is dis-
rupted in various pathophysiological conditions. Likewise, several 
oxidative stress sources converge and foster each other, creating a vi-
cious cycle that results in insulin insensitivity and impaired insulin 
secretion (in the case of β cells). A comprehensive discussion of these 
potential mechanisms has been provided elsewhere [34–45]. 
In addition to chronic elevations in circulating glucose and free fatty 
acid (FFA) levels, T2DM patients suffer from late diabetic complications 
across peripheral tissues [46,47]. Recent evidence suggests that com-
mon stress-activated signaling pathways such as nuclear factor-kappa B 
(NF-κB), p38 mitogen-activated protein kinases (p38 MAPK), and 
NH2-terminal Jun kinases (JNK)/SAPK underlie the development of 
most diabetic complications. Moreover, a chronic increase of FFA in 
obesity instigates similar redox-dependent stress pathways impairing 
insulin sensitivity and secretion [31]. 
5. Redox diseases need redox biomarkers 
Advances in redox biology unequivocally indicate that all metabolic 
diseases, obesity, and related metabolic syndrome, as well as diabetes, 
can be considered redox diseases. Impaired redox regulation is coupled 
with metabolic dysregulation and vice versa. Both are at the core of the 
disease pathogenesis, initiators of dysfunction, and mediators of pro-
gression that contribute to further complications. It is necessary to 
develop functional redox biomarkers that would reflect adipose tissue 
function to screen a "crime scene" where many morbidities actually 
begin. Current research focuses on identifying redox biomarkers, spe-
cific for etiology and pathogenesis of distinct metabolic diseases, stan-
dardization of their measurement, and selection as clinically acceptable 
biomarkers. Underlying oxidative stress in metabolic diseases is often 
evident as concomitant changes in both levels of RO(N)S and lipid, 
protein, and nucleic acid oxidation products as well as changes in levels 
of antioxidant defense components [48–52]. Therefore, all redox pa-
rameters that determine the level of prooxidants - RO(N)S and their 
biological effects can potentially be relevant redox biomarkers of 
metabolic diseases. Measurement of these parameters in biofluids such 
as serum, plasma, urine, and saliva can help predict, diagnose, treat, and 
monitor the progression of metabolic diseases as well as differentiate 
and provide a functional link between obesity, metabolic syndrome, and 
diabetes [53]. 
Fig. 3. From redox physiology to redox medi-
cine in obesity, metabolic syndrome, and type 2 
diabetes. In physiological states, the production of 
reactive species, metabolic processes, antioxidant 
defense responses, and repair/removal of oxida-
tively damaged biomolecules are highly synchro-
nized processes. In metabolic diseases, this 
homeostasis is disturbed. Nutrient overload disrupts 
redox/metabolic equilibrium. Gluco- and lipo- 
toxicity are an integrative part of the over-
production of reactive species, forming a vicious 
circle in which oxidative stress is central. Induction 
of secondary pathways of glucose and lipid meta-
bolism strongly enhances these processes, leading to 
oxidative stress and oxidative modification of all 
biomolecules, further inducing alterations in redox- 
metabolic regulation. T2DM: type 2 diabetes mel-
litus; ETC: electron transport chain; GSH: gluta-
thione; GSH-Px: glutathione peroxidase; GR: 
glutathione reductase; NOS: nitric oxide synthase; 
NOX: NADPH oxidase; PPP: pentose phosphate 
pathway; Prdx: peroxiredoxin; SOD: superoxide 
dismutase; TR: thioredoxin reductase; Trx: 
thioredoxin.   
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Altered activity, expression, and specific gene variants of antioxidant 
enzymes, and oxidative modifications of mitochondrial DNA (mtDNA) 
have been investigated as potential biomarkers of metabolic diseases. 
Reduced activity of antioxidant enzymes, namely superoxide dismutase 
(SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), and a 
significant decrease in the GSH/GSSG ratio, were found in peripheral 
blood mononuclear cells in obese individuals [54]. Additionally, these 
redox parameters are associated with metabolic functions of adipose 
tissue and the overall risk of metabolic syndrome. Higher basal GSH 
level and GSH-dependent enzyme activities were found in visceral adi-
pose tissue (VAT) than in subcutaneous adipose tissue (SAT), while these 
intercepted differences in thiol-redox parameters reflect a higher tri-
acylglycerol turnover in VAT depots [55]. In obese individuals, lower 
GSH levels in VAT were coupled with lower manganese superoxide 
dismutase (MnSOD) and higher NADPH oxidase protein expression. 
Interestingly, low CAT protein expression in VAT was specific to 
"metabolically obese" individuals (based on the BMI, Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR) index, triacylglycerol, 
total-, LDL- and HDL-cholesterol levels), in both lean and obese subjects 
with high metabolic risk. In contrast, increased MnSOD activity associ-
ated with a higher degree of mtDNA oxidative damage was found in 
peripheral blood mononuclear cells of T2DM patients with late diabetic 
complications [56]. Increased glutathione S-transferase (GST) activity 
was found in the plasma of individuals with T2DM [57], while increased 
plasma GSH-Px activity was associated with improved renal function in 
T2DM patients with hypertension as a result of vitamin E and/or sele-
nium supplementation [58]. Copper-zinc superoxide dismutase (CuZn-
SOD) polymorphisms were found to be associated with increased plasma 
copper concentrations in patients with newly diagnosed impaired 
glucose regulation and T2DM [59]. Furthermore, studies of the MnSOD, 
extracellular SOD, and CAT polymorphisms showed specific molecular 
association with diabetic neuropathy in T1DM patients [60]. 
Oxidation products of lipids, fatty acids, and nucleic acids are useful 
in characterizing and monitoring obesity as well as detecting prediabetic 
state and predicting associated health complications [61]. Higher levels 
of MDA in monocytes and F2-Isoprostanes (F2-IsoPs) and 8-oxo-2’--
deoxyguanosine (8-oxo-dG) in urine were found in obese patients, where 
8-oxo-dG showed potential for metabolic status monitoring since it 
correlated directly with glucose, insulin, HOMA index, and body weight 
and inversely with weight loss and antioxidant activities in morbidly 
obese patients undergoing bariatric surgery [54]. Moreover, serum 
levels of 8-oxo-dG and MDA were found to be increased in the serum of 
prediabetic subjects with high sensitivity for C-reactive protein and 
reduced GSH levels, implicating these redox markers as candidates for 
the diagnosis of prediabetes, as they correlated with glucose intolerance 
[62]. Similar disturbances in redox homeostasis are found in T2DM. 
High levels of oxidative DNA damage in lymphocytes of diabetic pa-
tients were found to be directly associated with serum lipid peroxidation 
and protein oxidation levels and inversely with SOD activity and protein 
thiol group content [63]. In another study, increased excretion of uri-
nary markers of DNA (8-oxo-dG) and RNA (8-oxo-Guo) oxidation was 
found in children and adults, which particularly correlated with age and 
female sex. The authors reported a very interesting finding that obesity 
in children with insulin resistance correlates with higher levels of 
oxidation RNA markers, which could be predictive of T2DM [64]. 
Other redox biomarkers showed promise in monitoring the devel-
opment of insulin resistance and diabetes progression. Long-term 
treatment of human primary preadipocytes from obese SAT with phys-
iological concentrations of 4-HNE caused increased oxidative stress, 
inhibition of cell growth, loss of adipogenic capacity, and impairment of 
insulin sensitivity [65]. A higher level of 4-HNE was found in VAT of 
overweight/obese premenopausal women, in comparison to 
normal-weight women, irrespectively of metabolic syndrome risk fac-
tors [55]. Such changes were associated with lower levels of GSH and 
MnSOD and high NADPH oxidase protein expression levels. In contrast, 
a significant increase in 4-HNE was found in the SAT of morbidly obese 
premenopausal women, but again irrespective of metabolic syndrome 
risk factors [65]. Therefore, 4-HNE in VAT is related to VAT dysfunction 
and oxidative stress even at low BMI, leading to restricted lipid buffering 
function of adipose tissue and increased lipid peroxidation as a function 
of BMI increase. In T2DM patients, higher serum levels of 4-HNE were 
found to directly correlate with clinical prognostic parameters (glycated 
hemoglobin, fasting glucose) [66]. However, the role of 4-HNE in 
metabolic diseases has not yet been fully elucidated and is probably 
concentration-dependent. At low physiological concentrations, it plays a 
crucial role in redox homeostasis, acting as a signaling molecule and 
inducing an adaptive response in diabetes, while at high concentrations, 
it exhibits cytotoxicity due to its high reactivity and can cause adipocyte 
dysfunction and insulin resistance [67,68]. This is true not only in dia-
betes but in other pathophysiological conditions, such as Rett syndrome 
and aging. For example, high levels of plasma 4-HNE protein adducts 
were found to increase with disease progression in subjects affected by 
Rett syndrome [69]. Moreover, our group previously showed that high 
levels of 4-HNE correlate with degenerative cutaneous tissue changes 
and oxidative DNA damage with advanced age, which is not the case in 
young animals [70]. 
Many of the commonly analyzed lipid peroxidation products are 
often found in different metabolic diseases. However, additional 
research will be necessary to assess their utility in differentiating be-
tween obesity, metabolic syndrome, and diabetes or their potential to 
predict the development of diabetes in patients with obesity and meta-
bolic syndrome. Importantly, several emerging studies highlight that 
specific parameters of lipid peroxidation could be used to achieve such 
stratifications. The development of metabolic syndrome in obese in-
dividuals can be predicted from a linear combination of visceral fat 
thickness and serum thiobarbituric acid reactive substances (TBARS): 
cholesterol ratio [50]. Low levels of plasma vitamin C and nitro-
soglutathione were found to be inversely correlated with the grade of 
hypertension in patients with metabolic syndrome, possibly discrimi-
nating between patients with low and high risk for diabetes and car-
diovascular complications [50]. Interestingly, the results from the 
Framingham study indicated that urinary 8-epi-prostaglandin F2α 
(8-epi-PGF2α) levels were highly associated with BMI and cardiovas-
cular complications, but not with diabetes [71]. Moreover, these redox 
changes seem to be closely related to the type of obesity. Furukawa et al. 
were the first to demonstrate that obesity exacerbates systemic markers 
of oxidative stress in a feedback loop leading to metabolic syndrome 
[72]. Several studies since then found correlations of lipid peroxidation 
markers with abdominal [73], but not with general obesity [74]. 
Moreover, it was found that increased fat mass with visceral distribution 
is specifically associated with systemic chronic low-grade inflammation 
and oxidative stress markers [50,71,75], highlighting the importance of 
redox and inflammatory pathways cross-talk, a phenomenon recently 
termed "OxInflamation" [76]. For example, urinary 8-epi-PGF2 levels 
were particularly associated with the visceral fat area, even in non-obese 
subjects. Similarly, a significant correlation of urine 8-epi-PGF2α and 
inflammation associated with lipid peroxidation-mediated platelet 
activation was seen in obese women with the android type of obesity, 
indicating a higher risk of developing hypercholesterolemia, diabetes 
mellitus, and vascular complications [77]. 
In a hyperglycemic environment, reactive carbonyl species (RCS) are 
readily generated, and subsequently, advanced glycation end products 
and protein carbonyl (PCO) content represent important biomarkers in 
diabetes and associated syndromes [78]. High levels of PCO, advanced 
oxidation protein products, and lipid hydroperoxides accompanied by a 
lower total thiol content in T2DM patients with poor glycaemic control 
were identified as important prognostic redox biomarkers for the 
development of diabetic complications [79]. In an exciting study of 
nutrition-mediated redox control in T2DM, a high-protein diet was 
found to reduce plasma MDA and protein carbonyls levels but increase 
nitrotyrosine levels [80]. A direct association of carbonyl stress with 
increased risk of the acute coronary syndrome was found in T2DM 
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patients, evident as an increase in methylglyoxal, methylglyoxal derived 
hydroimidazolones-1, and Nε-carboxymethyl-lysine serum levels [81]. 
Additionally, lower levels of GAPDH, glyoxalase 1, and aldehyde 
reductase suggest that metabolic disturbance precedes the development 
of acute coronary syndrome through RCS, while elevated levels of AGEs 
and protein carbonyls in vitreal fluid of T1DM and T2DM patients sug-
gests their role in proliferative diabetic retinopathy development [82]. 
Furthermore, reduced NO bioavailability is recognized as one of the 
key factors that contribute to disturbed redox homeostasis in metabolic 
diseases, especially diabetes. In an excellent review of human studies 
investigating NO metabolism in metabolic diseases, Kobayashi summa-
rizes the effects of endothelial nitric oxide synthase (eNOS) poly-
morphisms in a wide range of conditions (T2DM, IR, obesity) with 
modifications at the molecular level [83]. There is a clear association 
between eNOS polymorphisms with altered NOS activity, increased IR, 
and the incidence of metabolic syndrome and T2DM. In contrast, the 
level of asymmetric dimethylarginine, an endogenous NOS inhibitor 
found in all cells and plasma, is increased, while NO production is 
decreased in insulin resistance. In addition, specific alternations in NO 
metabolism were found in T2DM (decreased neuronal nitric oxide 
synthase-nNOS protein expression in skeletal muscle) and obesity 
(reduced NO availability and reduced eNOS expression in skeletal 
muscle). Although rare, existing human studies confirm the role of the 
L-arginine/NO pathway in diabetes, showing that long-term oral 
L-arginine supplementation improves endothelial function, oxidative 
stress, and adipokine release in obese T2DM patients with insulin 
resistance [84]. Besides, an increased level of NO (measured indirectly) 
correlates with T1DM (saliva and plasma) [85,86] and T2DM (saliva) 
[86], while salivary NO level is lower in T2DM subjects with xerostomia 
[87]. Demonstrated reduced NO bioavailability in diabetes [88] could 
be influenced by another important player in diabetes pathogenesis that 
has biomarker potential, calcium. Indeed, the overall calcium meta-
bolism was found to be disturbed in T1DM and T2DM, from decreased 
intestinal absorption to increased urinary excretion [89]. However, 
there is currently no consensus on the functional significance of plasma 
calcium alterations in diabetic patients. Interestingly, all three NOS 
isoforms are regulated by calcium, of which eNOS and nNOS directly via 
calcium-calmodulin [90], where an increase in calcium concentration is 
linked directly to NO production by eNOS [91]. However, this link is still 
controversial since other calcium-independent mechanisms are involved 
in regulating NOS activity: phosphorylation, availability of L-arginine, 
other reactive species, and oxidatively damaged biomolecules [90], 
many of which are disturbed in diabetes. Therefore, the synergistic ef-
fects of calcium-dependent and independent mechanisms likely impact 
altered NO homeostasis in diabetes. In addition to the NO and NO me-
tabolites, hydrogen sulfide (H2S) should be further investigated as a 
potential redox biomarker in diabetes since H2S concentrations, simi-
larly to NO, regulate a wide range of functions and are reduced in the 
plasma of patients with T2DM [92]. 
6. Lipofuscin as a novel redox biomarker of insulin-related 
metabolic diseases 
Lipofuscin is a non-degradable cellular material composed of 
oxidized proteins, lipids, and metals stored in lysosomes, whose accu-
mulation has been widely regarded as a hallmark of cellular aging [93]. 
The question has been posed whether lipofuscin can be repurposed as a 
biomarker of metabolic diseases that could predict the progression of 
obesity, metabolic syndrome, and diabetes. Nowadays, the contribution 
of pathological accumulation of lipofuscin is highlighted for many 
age-related diseases and complex conditions, which can also be regarded 
as metabolic diseases, including Alzheimer’s and Parkinson’s disease 
[94], denervation atrophy [95], inherited juvenile form of macular 
degeneration [96], lipid myopathy [97], chronic obstructive pulmonary 
disease [98], and Melanosis coli [99]. 
In the search for novel redox biomarkers reflecting insulin-related 
metabolic diseases, lipofuscin could be a promising and reliable candi-
date. Namely, lipofuscinogenesis, the formation of lipofuscin, occurs 
mainly in metabolically sensitive organs such as the brain, heart, liver, 
and adipose tissue (Fig. 4). The presence, subcellular distribution, and 
lipofuscin content vary greatly in tissue- and cell-specific manner. Be-
sides, the amount of lipofuscin in specimens from individuals of the 
same age varies and could be linked to disease or diet variation, which 
are all associated with the rate of oxidative protein damage, mito-
chondrial functionality, proteasomal system, and lysosomal function-
ality [100]. 
The concept that the accumulation of lipofuscin in the cell is not only 
age-, but also metabolism-dependent is not new [100,101], given close 
relations between metabolic disorders and aging as well as the role of 
oxidative stress in metabolic syndrome [102,103]. Hyperinsulinemia is 
implicated in metabolic syndrome as a condition that precedes obesity 
and diabetes and is associated with pancreatic islet hyperplasia, and is 
thus recognized as an early indicator of metabolic dysfunction [104]. 
The association of hyperinsulinemia and insulin resistance to mito-
chondrial dysfunction [105] and iron levels through rapid and pro-
nounced stimulation of iron uptake and loading by adipocytes 
[106–108] is well established. Furthermore, transferrin receptors 
colocalize with glucose transporters and insulin-like growth factor II 
receptors in the microsomal membranes of cultured adipocytes, sug-
gesting that regulation of iron uptake by insulin occurs in parallel with 
its effects on glucose transport [109]. Indeed, obese people have 
increased iron levels [110,111] and become prone to IR and potentially 
harmful lipofuscinogenesis. 
Hyperinsulinemia represents a risk factor for cardiovascular disease, 
neurodegeneration, diabetes, and cancer [112], while this type of 
dysfunction is a commonly observed feature in several animal models 
for obesity and diabetes [113,114]. Diabetes results in lipofuscin accu-
mulation in various tissues and organs [115]. Since hyperinsulinemia is 
also part of those metabolic diseases [116,117], the molecular events 
linking insulin and lipofuscin accumulation warrant further investiga-
tion. Hyperinsulinemia drives an overproduction of hydrogen peroxide 
and increased iron uptake, creating a harmful milieu, which leads to 
oxidative damage. As a result, damaged organelles and macromolecules 
accumulate inside cells in the form of lipofuscin [100]. Since lipofuscin 
accumulates within lysosomes as an end product, it is assumed that it 
could not be removed [118,119] and could thus represent a hallmark 
redox biomarker of cellular aging [120–123]. 
Interestingly, some data shows that lipofuscin could be found in a 
soluble state in bodily fluids and quantified. Hegedus et al. [124] 
documented an increase of plasma lipofuscin levels in stored blood and 
quantified human plasma lipofuscin [125]. Recently, lipofuscin was 
measured in human plasma and saliva [126]. This data raises the 
question of the existence of extracellular lipofuscin and its origins. 
Extraneuronal lipofuscin was found in the brain samples, suggesting a 
possible physiological removal from the nerve cells to the capillary 
endothelium and its later elimination via phagocytosis by glia cells 
[127]. Indeed, recent findings have shown that lipofuscin could be 
exocytosed from the cardiomyocytes into circulation through capillary 
endothelium [128]. Hence, lipofuscin could be regarded as a promising 
redox biomarker of obesity and diabetes. The revival of non-invasive 
lipofuscin measurements in bodily fluids with accurate and reliable 
methods shows promise for monitoring insulin-related metabolic dis-
eases [129]. 
7. The NRF2 redox pathway at the crossroads between the 
antioxidant defense and energy metabolism 
The NRF2 pathway, a master regulator of cellular defense against 
oxidative and xenobiotic stresses, has emerged as a critical target of 
energy metabolism [130]. Nuclear factor (erythroid-derived 2)-like 2 
(NRF2), a cap-n-collar basic leucine zipper transcription factor, serves to 
mount a cellular defense response against environmental and 
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endogenous stressors. Under conditions of lower stress, NRF2 is 
sequestered in the cytoplasm by associating with Kelch-like ECH-asso-
ciated protein 1 (KEAP1) and Cullin 3 ubiquitin E3 ligase. Upon expo-
sure to electrophilic and oxidative stresses, NRF2 becomes released from 
its cytosolic repressor KEAP1 and translocates to the nucleus, where it 
forms a complex with MAF and JUN proteins. This leads to NRF2 
binding to antioxidant response elements (AREs) in numerous gene 
promoters and subsequent activation of diverse transcriptional pro-
grams, including activation of genes encoding phase 2 detoxification 
and antioxidant enzymes [131]. In addition, NRF2 regulates a large 
number of genes involved in gluconeogenesis and lipid metabolism as 
well as β-oxidation, mitochondrial biogenesis, and inflammation, pro-
cesses which show robust diurnal variation (Fig. 5) [130,132–134]. 
Whilst there is strong evidence for the role of NRF2/KEAP1 pathway in 
modulating adipogenesis, responses to high-fat diet (HFD), insulin 
sensitivity, and metabolic health, the direction of this control is con-
flicting in the literature. Previous research has shown that NRF2 inhibits 
adipogenic differentiation via activation of the aryl hydrocarbon re-
ceptor (AHR) pathway. Adipogenic stimulation of Nrf2 knockout (KO) 
mouse embryonic fibroblasts (MEFs) led to increased intracellular lipid 
accumulation and elevated expression of peroxisome 
proliferator-activated receptor gamma and CCAAT/enhancer binding 
protein α (Pparγ and Cebpα, respectively), whilst delayed adipogenesis 
was seen in Keap1 knockdown (KD) MEFs [135]. In line with these data, 
Xu et al. demonstrated that in MEFs isolated from mouse models of NRF2 
activation, Keap1-KD, and leptin (ob/ob)-Keap1-KD, adipogenesis was 
suppressed, and adipogenic genes, such as Pparγ, Cebpα, and fatty 
acid-binding protein 4 (Fabp4) were decreased [136]. The same study 
Fig. 4. Lipofuscinogenesis in obesity and type 2 diabetes. Lipofuscinogenesis in hepatocytes (A - arrow) and cardiomyocytes (D- LF) of obese mice and brown 
adipocytes of hyperinsulinemic rats (B -rectangle, E − LF) results in gradual lipofuscin accumulation (C). In hyperinsulinemia, a state preceding obesity and diabetes, 
excessive production of H2O2 and higher import of iron drive peroxidative damage of mitochondria (mth) and lipid bodies (LB) and lead to the formation of lipofuscin 
(LF) containing their undigested remnants and iron. White star – damaged, structurally altered lipid body (B) and mitochondria (D). (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 5. Schematic diagram depicting the inter-
connected roles of NRF2 and circadian clock 
machinery in diverse transcriptional programs 
implicated in obesity, metabolic syndrome, and 
diabetes. Several different transcriptional pro-
grams are regulated by both NRF2 and the circadian 
molecular clock through positive and negative 
feedback control in various cell types and tissues. 
NRF2 and the molecular clock are also involved in 
the bidirectional regulation of each other. The 
target transcriptional programs display ~24h os-
cillations in various components and range from 
antioxidant/detoxification and inflammatory re-
sponses to pathways involved in mitochondrial 
biogenesis/β-oxidation, adipogenesis/lipogenesis, 
as well as insulin and glucose-regulated pathways. 
NRF2: nuclear factor (erythroid-derived 2)-like 2.   
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demonstrated that pharmacological NRF2 activation by sulforaphane 
(SFN) prevented adipogenesis and lipid accumulation [136]. Additional 
NRF2 inducers such as carnosic acid and carnosol originating from dried 
rosemary leaves were also shown to inhibit adipogenic differentiation by 
stimulating glutathione metabolism [137]. 
In contrast, other research has shown that Nrf2 KO mice have lower 
amounts of adipose tissue and that mouse and human preadipocytes 
show suppressed adipocyte differentiation resulting from the down-
regulation of Pparγ and Cebpα expression following Nrf2 shRNAs whilst 
enhanced adipogenesis was seen with Keap1 shRNAs [138]. In line with 
this work, another study demonstrated NRF2 as a positive regulator of 
adipogenesis using preadipocytes derived from white adipose tissue 
[139]. 
Further to its role in adipogenesis and adipose tissue maintenance, 
NRF2 also plays an important role in modulating obesity. CDDO-Im, a 
potent NRF2 activator, was shown to prevent body weight gain and WAT 
increase in response to HFD in wild type mice [140]. Similar findings 
were found using another NRF2 inducer, oltipraz, which prevented in-
sulin resistance and weight gain in response to HFD [141]. Consistently, 
a number of other NRF2 inducers such as quercetin, curcumin, resver-
atrol, and chromium histidinate have all shown anti-obesity effects at 
least partially through NRF2 induction (reviewed in Ref. [142]). 
Surprisingly, some in vivo animal studies show a complex role of 
NRF2 in influencing responses to HFD. For example, Nrf2 KO mice were 
found to show blunted fat pad increases following HFD compared to 
wild-type mice, and this was independent of differences in food con-
sumption, intestinal fat absorption, and physical activity [138]. Simi-
larly, another study found that Nrf2 deficiency protects against 
HFD-induced obesity through fibroblast growth factor 21 and im-
proves glucose tolerance and insulin sensitivity [143]. On the other 
hand, Keap1-KD mice, which have increased NRF2 levels, also had lower 
body weights and fat masses than wild-type mice on HFD [136]. In line 
with this work, mice over-expressing NRF2 target, NAD(P)H quinone 
dehydrogenase 1 (Nqo1), conferred protection from diet-induced 
metabolic defects through the preservation of glucose homeostasis, in-
sulin sensitivity, and lipid handling with improved physiological out-
comes [144]. NQO1-overexpressing mice on HFD had lower adipose 
tissue macrophages and enhanced expression of lipogenic enzymes 
together with the reduction in circulating and hepatic lipids. 
In contrast, some reports have shown that NRF2/KEAP1 pathway has 
no effects on body weight in response to HFD feeding; however, Nrf2 KO 
mice were protected from HFD-induced hyperglycemia [145]. Whereas 
Nrf2 KO mice were resistant to HFD-induced glucose intolerance, Keap1 
KD mice exhibited prolonged elevation of circulating glucose during a 
glucose tolerance test, even on a control diet. Indeed, some reports agree 
that whole-body Nrf2 KO mice are more glucose-tolerant and 
insulin-sensitive than wild-type mice [143], whilst Keap1 KD mice on a 
background of leptin deficiency (a genetic model of obesity) showed 
higher glucose concentration than control mice [136]. On the other 
hand, mice with myeloid-selective Nrf2 deficiency were less sensitive to 
insulin, suggesting that NRF2 in myeloid cells acts negatively against the 
development of insulin resistance [146]. Interestingly, Nrf2 deletion 
impairs glucose tolerance and exacerbates hyperglycemia in type 1 
diabetic mice [147]. Indeed, NRF2 activation plays an important role in 
protection against autoreactive T-cell-induced T1DM using non-obese 
diabetic (NOD) mice, a polygenic model of human type 1 diabetes 
[148]. Keap1 KD mice inhibited T-cell infiltration, ameliorated impair-
ment of insulin secretion, and prevented the development of diabetes 
mellitus in NOD mice. This occurred through decreasing both plasma 
interferon-γ (IFN-γ) levels and IFN-γ-positive cell numbers in the 
pancreatic islets. 
To resolve some of the conflicting data on the role of NRF2/KEAP1 
pathway in obesity and metabolic health, studies have investigated the 
effect of Nrf2 deletion in a tissue-specific manner. Nrf2 deletion from 
adipocytes, but not hepatocytes, potentiated systemic metabolic 
dysfunction after long-term HFD-induced obesity in mice [149]. Mice 
with Nrf2 loss in adipocytes showed a partially deteriorated glucose 
tolerance, higher fasting glucose levels, and higher levels of cholesterol 
and non-esterified fatty acids. In contrast, mice with Nrf2 loss in hepa-
tocytes had lower insulin levels and improved insulin sensitivity without 
changes to liver triglyceride accumulation. Furthermore, another study 
investigated the role of NRF2 in influencing the risk of metabolic syn-
drome by using a whole-body or adipocyte-specific Nrf2 KO mice on a 
leptin-deficient ob/ob background, a model of extreme positive energy 
balance [150]. On ob/ob background, loss of Nrf2, globally or in adi-
pocytes, showed reduced WAT mass but led to a more severe metabolic 
syndrome with aggravated insulin resistance, hyperglycemia, and 
hypertriglyceridemia. These new studies have revealed that 
NRF2/KEAP1 pathway has differential effects on weight control and 
metabolic health in a cell-type-specific manner. 
Pharmacological NRF2 activation has shown more consistent out-
comes regarding their protective effects on metabolic health. An NRF2 
inducer SFN reversed disease signature in diabetic livers and attenuated 
exaggerated glucose production and glucose intolerance. Importantly, 
SFN reduced fasting blood glucose and HbA1c in obese patients with 
dysregulated T2DM [132]. Another NRF2 inducer, oltipraz, improved 
glucose metabolism and prevented insulin signaling impairments in 
mice on HFD [141]. Similarly, curcumin improved insulin sensitivity 
through the regulation of muscular mitochondrial redox balance; ellagic 
acid protected against HFD-induced metabolic syndrome and NRF2 
agonist Dh404 prevented insulin resistance (reviewed in Ref. [142]). 
Although pharmacological NRF2 activation has shown promising results 
in several animal and human studies, the synthetic NRF2 inducers have 
caused adverse cardiac events and gastrointestinal toxicities in clinical 
trials [151]. Alternative supplementation with glucoraphanin, a stable 
precursor of SFN, attenuated weight gain, increased energy expenditure, 
and core body temperature led to improved glucose tolerance and in-
sulin sensitivity in HFD-fed wild-type mice. This occurred via activating 
insulin-stimulated Akt phosphorylation in the liver, muscle, and WAT 
and preventing uncoupling protein 1 protein reduction in WAT. Glu-
coraphanin was also able to reduce circulatory levels of lipopolysac-
charide, attenuate inflammatory signaling pathways such as JNK and 
extracellular signal-regulated kinase (ERK), and inflammation-activated 
M1-like macrophage accumulation in liver and adipose tissue. Finally, 
glucoraphanin was able to reduce hepatic elevated lipogenic gene 
expression, lipid peroxidation levels of MDA, and expression of NADPH 
oxidase subunits [151]. 
Overall, whilst some of the discrepancies in the above studies may 
result from the use of different cell types (e.g., primary vs. immortalized, 
MEFs vs. adipocytes), mouse genetic backgrounds as well as the length 
or types of HFD (milk fat vs. lard), it is important to note that most 
studies do not specify the gender or age of animal models used. More-
over, responses to HFD as well as various outputs of energy metabolism 
show profound time-of-day circadian differences, which is another 
important confounding factor to take into consideration. Therefore, 
future studies are urgently needed to decipher the precise temporal and 
cell-type-specific role of NRF2 and its target molecular mechanisms in 
regulating adipose tissue homeostasis and responses to HFD and deter-
mine how gender and age modulate this regulation. 
8. Energy metabolism and redox regulation as a function of 
~24h circadian rhythms 
Circadian rhythms govern ~24h rhythms in daily human and 
mammalian physiology, metabolism, and behavior both in health and 
disease, including the daily rhythms in feeding activity, hormone pro-
duction, and glucose metabolism [152]. The circadian timing co-
ordinates temporal variation in biochemical processes with changes in 
nutrient intake in order to optimize energy balance and maintain 
metabolic homeostasis [153]. The circadian timing system consists of a 
central brain clock in the anterior hypothalamic suprachiasmatic nu-
cleus (SCN) and various peripheral tissue clocks, which drive 
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positive/negative feedback loops in transcription/translation and 
metabolite abundance [154]. The central clock regulates food intake, 
energy expenditure, whole-body insulin sensitivity, and glucose ho-
meostasis, whilst the local peripheral clocks also contribute to this 
regulation and fine-tune these processes. Some examples include the 
peripheral clock in the gut, which regulates glucose absorption, pe-
ripheral clocks in muscle, adipose tissue, and liver, which regulate local 
insulin sensitivity, and the peripheral clock in the pancreas which reg-
ulates insulin secretion [155–157]. 
Misalignment between circadian timing system and daily rhythms of 
sleep-wake behavior or food intake as a result of genetic, environmental, 
or behavioral circadian disruptions is associated with metabolic disor-
ders such as obesity, insulin resistance, and diabetes [158]. Indeed, 
disrupted circadian rhythms of body temperature, heart rate, and fasting 
blood glucose are seen in both prediabetes and T2DM [159]. Moreover, 
emerging work has shown that chrono-based nutritional interventions 
such as time-restricted feeding can rescue obesity and metabolic syn-
drome in mice lacking a genetic circadian clock [156,157]. 
Current high-throughput technologies have allowed for the dynamic 
monitoring of diverse cellular processes over ~24h daily cycle, ranging 
from gene and protein expression to metabolite abundance, thus 
discovering potential circadian biomarkers. Indeed, ~40% of the 
genome is under circadian control across different mammalian tissues 
[160]. For example, circadian metabolomes have been reported for 
human serum, saliva, breath, and urine, as well as tissues from several 
species in different disease conditions and following genetic disruption 
[161]. Circadian proteomics of plasma proteins from human partici-
pants undergoing simulated night shift work showed 24h time-of-day 
patterns in 573 of 1129 proteins analyzed and revealed that circadian 
misalignment altered multiple proteins known to regulate glucose ho-
meostasis and/or energy metabolism, with implications for altered 
metabolic physiology [162]. Social jetlag, a measure of disruption of the 
circadian system, has been associated with increased fasting glucose 
levels and a higher risk of overweight and metabolically obese status in a 
study with ~792 Brazilian participants [163]. Elevation of circulating 
FFA levels is associated with insulin resistance and diabetes risk [164]. 
FFA levels in healthy individuals show strong circadian variation, and 
sleep restriction relative to normal sleep led to its increased levels in 
nocturnal and early morning hours. This was associated with prolonged 
secretion of nocturnal growth hormone levels and early morning 
noradrenaline levels [164]. A recent genome-wide association study of 
reported day-time sleepiness analyzing 452,071 individuals from the UK 
Biobank has identified 42 genetic loci that clustered into specific bio-
logical subtypes and shared genetic links with several chronic diseases, 
including diabetes [165]. 
Previous work has characterized ~24h time-of-day variation and the 
effects of sleep deprivation on urinary metabolite profiles in healthy 
male participants under highly controlled environmental conditions by 
1H NMR spectroscopy [166]. Significant changes were observed with 
respect to both time-of-day and sleep deprivation, indicating that sam-
pling time and sleep deprivation are highly relevant when identifying 
biomarkers in metabolic profiling studies. Further work by the same 
group using targeted liquid chromatography/mass spectrometry 
metabolomics identified 130 plasma metabolites every 2h over 24h, and 
showed that average metabolite concentrations were significantly 
altered by increased body mass (90 of 130) and T2DM (56 of 130). 
Moreover, ~40% of plasma metabolites showed daily rhythms, high-
lighting the importance of controlling the time-of-day for diagnosis and 
biomarker discovery [167]. In addition, a complementary study iden-
tified using untargeted and targeted liquid chromatography (LC)/MS 
metabolomics that acute sleep deprivation reduced amplitude of 
rhythms of >50% of rhythmic plasma metabolites identified [168]. The 
altered metabolite rhythms in overweight and T2DM individuals is 
consistent with previous work showing that individuals with T2DM have 
lower night-time serum melatonin levels and an increased risk of co-
morbid sleep disturbances compared with healthy individuals [169]. 
Moreover, the effects of sleep restriction and loss were also examined 
using RNAseq profiling of WAT transcriptome between day and night. 
This has shown that sleep restriction blunts the normal daily variation in 
WAT transcriptome and that sleep deprivation led to further dampening 
[170]. This resulted in uncoupling of the clock-controlled regulated 
pathways of carbohydrate and lipid metabolism from the adipose tissue 
clock, leading to increased carbohydrate turnover and impaired glucose 
homeostasis [170]. In line with this work, human mature adipocytes 
show altered circadian rhythms in obese patients with age [171]. 
Similarly, a further study investigated whether the expression of clock 
genes in peripheral blood cells is impaired in T2DM and whether in-
flammatory markers are associated with circadian clock gene expression 
in T2DM patients. This study revealed that a number of core clock genes 
was decreased in leukocytes of T2DM patients, which was correlated 
with elevated levels of plasma inflammatory markers such as interleukin 
6 and tumor necrosis factor α [172]. 
Circadian rhythms are highly interconnected to redox homeostasis, 
and this is demonstrated to be a bidirectional process as many metab-
olites and products of oxidative metabolism, as well as components of 
redox pathways, can feedback and influence circadian timing 
[173–177]. Recently we and others demonstrated that circadian mo-
lecular machinery regulates endogenous rhythms in NRF2 protein and 
transcript levels in several metabolic tissues, including the liver, lung, 
pancreas, and heart [158,178–180]. Moreover, we have shown that 
target antioxidant genes oscillate in tissues and cells in an 
NRF2-dependent manner [179], which is coupled to the daily oscillatory 
changes in cellular and tissue ROS levels [175]. In addition, we and 
others have observed redox oscillations in protein carbonylation marker 
and glutathione redox states in mouse tissues as well as human cells and 
bodily fluids [179,181–184]. 
A number of additional potential redox biomarkers have also been 
shown to be under circadian control. Circadian variation in lipid per-
oxidation marker MDA is observed in mouse erythrocytes [185] as well 
as in healthy human volunteers. Circadian control of plasma lipid per-
oxides (MDA) and serum ascorbic acid and uric acid levels were reported 
[186]. Night shift workers have lower levels of antioxidant defense 
components and higher levels of TBARS when compared to day workers 
[187]. Plasma TBARS concentrations are increased in the fasting state in 
obese men [188] whilst bariatric surgery reduced both TBARS and 
protein carbonyl concentrations in obese individuals [189]. Further-
more, the measurement of ~24h urinary excretion of 8-oxo-G oxidative 
damage marker suggests that obesity in men is also associated with 
increased oxidative damage to RNA [190]. The removal of oxidative 
damage to DNA/RNA such as 8-oxoguanine via the DNA base excision 
repair pathway is also under the circadian influence [191]. Altogether, 
these findings urge further work to examine the circadian rhythmicity of 
diverse redox biomarkers and antioxidant defense components in 
human research and animal models of metabolic diseases as well as test 
the potential of chrono-nutritional interventions in human clinical trials. 
9. Cancer as a metabolic disease: deciphering the intriguing 
relationship with obesity, metabolic syndrome, and diabetes 
through redox biomarkers 
The cumulative burden of neoplastic and metabolic diseases is hard 
to grasp, but current predictions do not seem optimistic [192,193]. 
Cancer is predicted to pose a higher threat to human health than car-
diovascular diseases by 2030 [194]. Whilst obesity and diabetes take on 
epidemic proportions, evidence supporting the association between 
metabolic disorders and cancer has also accumulated. Prospective 
observational studies and meta-analyses show that obesity increases 
incidence [195,196] and mortality [197] for many cancers. Likewise, 
there is substantial evidence linking diabetes and cancer [198], although 
the association is more complicated to dissect, primarily due to the 
confounding influence of obesity on both diabetes and cancer develop-
ment. In general, the association of site-specific cancers with obesity 
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further increases in diabetes, including colorectal, pancreatic, liver, gall 
bladder, kidney, breast, and endometrial [199,200]. The relationship 
becomes even more complicated when different antidiabetic and anti-
neoplastic treatments are considered [201,202]. 
In light of the abundant epidemiological data and critical research 
highlighting metabolic reprogramming and redox regulation as two 
inseparable phenomena in cancer, the view has gradually shifted to-
wards contemplation of cancer as a redox-metabolic disease [203–206]. 
Thus, obesity, metabolic syndrome, and diabetes could be regarded as 
potential driving forces for cancer development, acting through systemic 
and local influences on the tumor microenvironment [207,208]. Within 
this framework, it is not surprising that cancer-associated adipocytes 
emerged as critical players in cancer progression, especially for 
site-specific cancers strongly associated with obesity, such as colorectal 
[209], breast [210], and prostate [211]. 
Obesity-associated circulating levels of glucose, free fatty acids, in-
sulin, insulin-like growth factor 1 as well as adipose tissue inflammation 
and dysregulated cytokine and adipokine signaling are some of the 
mechanisms that link obesity and cancer and are extensively reviewed 
elsewhere [212,213]. More recently, research focus has shifted towards 
metabolic cross-talk as one of the integral aspects of cancer-adipose 
tissue two-way communication [214,215]. Several exciting studies, 
including our own, showed not only that metabolic support provided by 
adipocytes is instrumental for cancer progression and metastasis but that 
it is redox-sensitive [216–218] and obesity-mediated [219–221] 
(Fig. 6). Thus, disturbed redox regulation in cancer-adipose tissue 
cross-talk could provide one of the missing links between metabolic 
diseases and cancer. 
Great efforts were invested in identifying redox biomarkers that 
could predict cancer risk, stage of progression, and therapeutic outcome. 
Most commonly analyzed redox biomarkers are oxidation and glycation 
products of nucleic acids, proteins, and lipids in plasma, serum, urine, 
and saliva [222]. Results from prospective, case-control, and nested 
case-control studies provide valuable information about the potential of 
these biomarkers to serve as clinical parameters but often yield incon-
clusive or contradictory results. A crucial consideration is their useful-
ness in individuals with concomitant metabolic and neoplastic diseases 
since similar parameters are often used to differentiate obesity, meta-
bolic syndrome, diabetes, and several types of cancer. 
One of the most studied lipid peroxidation products, MDA, was found 
to be consistently elevated in plasma/serum of patients with breast 
[223], prostate [224,225], and colon cancer [226]. Among markers of 
nucleic acid oxidation products, serum level of 8-oxo-dG was found to be 
inversely associated with lymph node metastasis in breast cancer pa-
tients [227], while urinary levels were inversely associated with longer 
survival in colon cancer patients [228]. Measurement of advanced gly-
cation products also showed predictive potential in several types of 
cancer. A prospective nested case-control study showed an association 
between plasma Nε-carboxymethyl-lysine and the risk of prostate cancer 
[229], while Nε-carboxymethyl-lysine content in breast cancer tissue 
was associated with better prognosis with tamoxifen treatments and 
worse prognosis with chemotherapy [230]. Urinary levels of iso-
prostanes were generally associated with the cancer risk and stage of 
progression for breast [231], prostate [232,233], and colon cancer 
[234], although a recent large follow-up study found no association with 
these malignancies [235]. 
One of the challenges in the biomarker research field is that previ-
ously found associations are often lost when larger sample sizes are 
considered. For example, a case-control study found a direct association 
of urinary levels of 15-F2t-isoprostane, and an inverse association of 8- 
oxo-dG with breast cancer risk [231]. Two years later, the same group 
found no difference in urinary 15-F2t-isoprostane and 8-oxo-dG between 
breast cancer patients and controls in a large population-based case--
control study [236]. Another issue concerns the uniformity of study 
cohorts, especially regarding confounding factors such as obesity. This is 
nicely illustrated in an example where a large prospective nested 
Fig. 6. Schematic representation of obesity-driven cancer-adipose tissue cross-talk. Cancer cells exist within an intricate tumor milieu comprised of stromal 
constituents, namely extracellular matrix components and numerous stromal cell types, including fibroblasts, adipocytes, mast cells, dendritic cells, immune cells, 
and vascular endothelial cells, among others. Obesity can shape the tumor microenvironment through systemic and local influences acting on both cancer cells and 
adipocytes, thus (re)framing their cross-talk and (re)directing cancer proliferation, metastasis, and therapeutic resistance. Recently, a concept of metabolic coop-
eration was introduced to describe the nutritional and metabolic support provided by adipocytes through the supply of substrates for carbohydrate and lipid 
metabolism. Moreover, this cooperation seems to be supported by redox regulatory mechanisms and may include redox synchronization between cancer cells and 
adipocytes. Redox-metabolic profiling of cancer and adipose tissue could be instrumental in advancing personalized therapeutic approaches, especially for in-
dividuals with concomitant metabolic diseases such as obesity, metabolic syndrome, and diabetes. Glu: glucose; FFA: free fatty acids; IGF-1: insulin-like growth factor 
1; 4-HNE: 4-hydroxynonenal; ROS: reactive oxygen species; RNS: reactive nitrogen species. 
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case-control study found no differences in urinary levels of 15-F2t-iso-
prostane and 2,3-dinor-5,6-dihydro-15-F2t-IsoP between breast cancer 
patients and controls, but further analysis according to BMI revealed 
that high levels of isoprostanes increase the cancer risk for obese and 
decrease the cancer risk for normal-weight women [237]. Moreover, the 
same redox biomarkers may be indicative of some but not other types of 
cancer; such is the case with plasma protein carbonyls. Several studies 
found an increase in breast cancer risk in women with higher levels of 
plasma protein carbonyls [238,239], while a large randomized, 
placebo-controlled trial found no association with a prostate cancer risk 
[240]. 
We are beginning to appreciate the importance of complex metabolic 
diseases in shaping the tumor microenvironment, while the accompa-
nying research of underlying redox regulatory mechanisms is truly in its 
infancy. Nevertheless, results from recent comprehensive tran-
scriptomic, proteomic, and metabolomic studies emphasize the enor-
mous potential of individual profiling for cancer diagnostic and 
prognostic advancements, highlighting that study of redox-metabolic 
networks is a fertile ground for the search for biomarkers that will 
guide our approach in personalized therapy designs. More extensive 
population-based prospective and nested control-case studies employing 
multivariate analysis are needed to draw definite conclusions. 
10. Conclusions and future perspectives 
"All right, said the Cat; and this time it vanished quite slowly, 
beginning with the end of the tail, and ending with the grin, which 
remained some time after the rest of it had gone". 
Lewis Carroll (Alice in Wonderland) 
This quote illustrates the duality of present perspectives when we 
talk about redox biomarkers in complex disease conditions such as those 
related to obesity, metabolic syndrome, and diabetes. Currently, we are 
beginning to understand the redox bases of metabolic diseases but are 
encountering numerous challenges in validating redox biomarkers. 
These include overlapping of metabolic conditions, differential clinical 
presentation and progression, the involvement of a wide range of organs 
and organ systems, limitations in the availability of human biological 
samples, and the absence of reference values of redox biomarkers in 
healthy subjects, including diurnal variations. On the other hand, after 
decades of testing redox biomarkers in plasma/serum, blood cells, urine, 
saliva, and other bodily fluids and available biological material, some 
redox biomarkers are approaching the fulfillment of strict criteria [2]. 
The development of various redox methodologies and less invasive ap-
proaches in recent years is encouraging. In addition to measuring 
markers of oxidative damage to biomolecules and alterations in anti-
oxidant defense components, direct electrochemical measurement of 
reactive species (NO, H2O2, and even H2S) has become a real possibility 
today. The selection of representative sets of biomarkers for specific 
metabolic diseases and their standardization is one of the first steps 
warranting further research. Rigorous evaluation of redox proteomes, 
lipidomes, metabolomes, and transcriptomes will be of great help in 
deciphering the complex redox-metabolic landscapes. This should be 
preceded by the validation of redox biomarkers in healthy subjects, 
taking into account the influence of lifestyle (diet, physical activity, 
sleep, work patterns) and diurnal fluctuations in metabolites influenced 
by circadian rhythms. The development of new methodologies for 
determining redox biomarkers in tissue biopsies, such as adipose tissue, 
could eliminate some of the challenges related to the standardization of 
redox biomarkers in obesity, metabolic syndrome, and diabetes. 
Emerging advances in redox biology, both research-wise and methodo-
logically, allow us to be optimistic about the future of redox disease 
biomarkers in clinical medicine. 
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